John Johnson

Mr. Johnson is a recognized leader in the pharmaceutical and biotechnology industry, with more than three decades of experience, currently serving as Chief Executive Officer and Board Director of Reaction Biology. He served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson, responsible for the Biotechnology, Immunology, and Oncology commercial businesses. Previously, Mr. Johnson served as president of Eli Lilly & Company’s Worldwide Oncology Unit, following the company’s 2008 acquisition of ImClone Systems, Inc., where he served as Chief Executive Officer and a member of ImClone’s Board of Directors. He has served as a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of biotechnology Industry Organization (BIO). Mr. Johnson also served as Chairman, President, and Chief Executive Officer of Dendreon Corporation, and has held other executive roles within the biotech industry. Currently, he is a member of the Board of Directors of Xeris Biopharma Holdings, Inc (XERS) and Axogen, Inc (AXGN).